Half of the 2023 US pharmaceutical launch class underperformed their pre-launch first year forecast while 39% overperformed. However, this is an improvement from prior years, with 54% underperforming and 35% overperforming when evaluating new product launches in the US from 2020-2023. These are the findings of a whitepaper by life sciences analyst Trinity Life Sciences […]